Extending existing inventory controls to a new category
If your practice already tracks controlled substances with a named responsible party, a locked storage location, and a log from receipt to use, that structure can often be extended to a biologics line rather than designed from scratch.
Hold a new vendor's documentation to whatever audit standard your practice already uses internally, rather than treating biologics as a separate, lower-scrutiny category.
- Consider extending existing inventory-logging structures to biologics
- Assign one named person to approve new vendors and categories
- Store biologics inventory under the same access controls as other regulated supplies, if applicable
- Compare a new vendor's documentation against your existing audit standard
Evaluating documentation turnaround
Ask how quickly a vendor can produce a certificate of analysis and lot release record, and consider requesting sample documentation during evaluation rather than after the first order ships.
Confirm donor eligibility summaries are available per lot, not only at the product-line level, since each lot carries its own identifier and release record.
- Ask for a sample certificate of analysis before the first order
- Ask how documentation requests are handled during evaluation
- Confirm donor eligibility summaries are available per lot
- Include documentation responsiveness in your vendor evaluation
Planning inventory around procedural scheduling
If procedures are scheduled in blocks, ask about a vendor's typical order-to-delivery window so stock can be planned ahead of procedure days without overordering.
Cryopreserved and lyophilized formats carry different planning considerations: one depends on freezer space and dry-ice delivery timing, the other on shelf-stable storage.
- Ask about order-to-delivery windows relative to your procedure schedule
- Confirm freezer capacity against any planned cryopreserved orders
- Consider lyophilized formats if storage space is constrained
- Match stock levels to scheduled volume rather than overordering
Confirming regulatory posture with counsel, not the vendor
Familiarity with regulatory scrutiny in one area does not substitute for a review of how a specific product and intended use map to 21 CFR 1271.10. Whether a specific intended use meets all applicable criteria is a determination for the practice and its counsel.
These products are not FDA approved or licensed for any disease or condition. Information here is for licensed healthcare professionals and is not medical or legal advice.
- Treat biologics as its own regulatory review, not an extension of other categories
- Confirm state board requirements with counsel before the first order
- Avoid relying on a vendor for clinical or regulatory interpretation
- Revisit the regulatory review if intended use changes
Frequently asked questions
Can existing controlled-substance logging be reused for biologics inventory?+
Possibly. Practices sometimes adapt the same structure, named responsible party, secured storage, and a per-unit log, but confirm the specifics fit a biologics category rather than assuming the categories are regulated identically.
What documentation turnaround should a practice ask about?+
Ask the vendor directly what its typical turnaround is for a certificate of analysis and lot release record, and consider testing this during evaluation before placing a regular order.
Who should approve a new biologics vendor?+
That is a decision for the practice to make and document, often following whatever approval chain it already uses for other regulated inventory.